Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
2012-001646-18Phase 3Terminated
- Sponsor
- GSK
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Ambrisentan 5 mg with Placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk distance at week 16. Started Apr 2013; status: terminated.
02
Drugs
ambrisentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2012-001646-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001646-18.